Using modafinil to treat fatigue in parkinson disease: A double-blind, placebo-controlled pilot study

Jau Shin Lou, Diana M. Dimitrova, Byung Park, Sarah C. Johnson, Ryan Eaton, Grace Arnold, John Nutt

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

BACKGROUND:: Fatigue is a major nonmotor symptom in Parkinson disease (PD). It is associated with reduced activity and lower quality of life. OBJECTIVE:: To determine if modafinil improves subjective fatigue and physical fatigability in PD. METHODS:: Nineteen PD patients who reported significant fatigue in the Multidimensional Fatigue Inventory (MFI) participated in this 8-week study. Subjects took their regular medications and were randomly assigned to the treatment group (9 subjects, modafinil 100-mg capsule BID) or placebo group (10 subjects). We used the MFI to measure subjective fatigue and used finger tapping and intermittent force generation to evaluate physical fatigability. Subjects also completed the Epworth Sleepiness Scale (ESS) and the Center of Epidemiological Study-Depression Scale. RESULTS:: There were no significant differences at baseline and at 1 month in finger tapping and ESS between the modafinil and placebo groups. At 2 months, the modafinil group had a higher tapping frequency (P <0.05), shorter dwell time (P <0.05), and less fatigability in finger tapping and tended to have lower ESS scores (P <0.12) than the placebo group. However, there was no difference between groups over time for any dimension of the MFI. CONCLUSIONS:: This small study demonstrated that although modafinil may be effective in reducing physical fatigability in PD, it did not improve fatigue symptoms.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalClinical Neuropharmacology
Volume32
Issue number6
DOIs
StatePublished - Nov 2009

Fingerprint

Fatigue
Parkinson Disease
Placebos
Fingers
Equipment and Supplies
modafinil
Capsules
Epidemiologic Studies
Quality of Life

Keywords

  • Fatigue
  • Parkinson disease/parkinsonism
  • Quality of life

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Using modafinil to treat fatigue in parkinson disease : A double-blind, placebo-controlled pilot study. / Lou, Jau Shin; Dimitrova, Diana M.; Park, Byung; Johnson, Sarah C.; Eaton, Ryan; Arnold, Grace; Nutt, John.

In: Clinical Neuropharmacology, Vol. 32, No. 6, 11.2009, p. 305-310.

Research output: Contribution to journalArticle

Lou, Jau Shin ; Dimitrova, Diana M. ; Park, Byung ; Johnson, Sarah C. ; Eaton, Ryan ; Arnold, Grace ; Nutt, John. / Using modafinil to treat fatigue in parkinson disease : A double-blind, placebo-controlled pilot study. In: Clinical Neuropharmacology. 2009 ; Vol. 32, No. 6. pp. 305-310.
@article{0e439ee91e174e9cac4c5bcc9ccd2cec,
title = "Using modafinil to treat fatigue in parkinson disease: A double-blind, placebo-controlled pilot study",
abstract = "BACKGROUND:: Fatigue is a major nonmotor symptom in Parkinson disease (PD). It is associated with reduced activity and lower quality of life. OBJECTIVE:: To determine if modafinil improves subjective fatigue and physical fatigability in PD. METHODS:: Nineteen PD patients who reported significant fatigue in the Multidimensional Fatigue Inventory (MFI) participated in this 8-week study. Subjects took their regular medications and were randomly assigned to the treatment group (9 subjects, modafinil 100-mg capsule BID) or placebo group (10 subjects). We used the MFI to measure subjective fatigue and used finger tapping and intermittent force generation to evaluate physical fatigability. Subjects also completed the Epworth Sleepiness Scale (ESS) and the Center of Epidemiological Study-Depression Scale. RESULTS:: There were no significant differences at baseline and at 1 month in finger tapping and ESS between the modafinil and placebo groups. At 2 months, the modafinil group had a higher tapping frequency (P <0.05), shorter dwell time (P <0.05), and less fatigability in finger tapping and tended to have lower ESS scores (P <0.12) than the placebo group. However, there was no difference between groups over time for any dimension of the MFI. CONCLUSIONS:: This small study demonstrated that although modafinil may be effective in reducing physical fatigability in PD, it did not improve fatigue symptoms.",
keywords = "Fatigue, Parkinson disease/parkinsonism, Quality of life",
author = "Lou, {Jau Shin} and Dimitrova, {Diana M.} and Byung Park and Johnson, {Sarah C.} and Ryan Eaton and Grace Arnold and John Nutt",
year = "2009",
month = "11",
doi = "10.1097/WNF.0b013e3181aa916a",
language = "English (US)",
volume = "32",
pages = "305--310",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Using modafinil to treat fatigue in parkinson disease

T2 - A double-blind, placebo-controlled pilot study

AU - Lou, Jau Shin

AU - Dimitrova, Diana M.

AU - Park, Byung

AU - Johnson, Sarah C.

AU - Eaton, Ryan

AU - Arnold, Grace

AU - Nutt, John

PY - 2009/11

Y1 - 2009/11

N2 - BACKGROUND:: Fatigue is a major nonmotor symptom in Parkinson disease (PD). It is associated with reduced activity and lower quality of life. OBJECTIVE:: To determine if modafinil improves subjective fatigue and physical fatigability in PD. METHODS:: Nineteen PD patients who reported significant fatigue in the Multidimensional Fatigue Inventory (MFI) participated in this 8-week study. Subjects took their regular medications and were randomly assigned to the treatment group (9 subjects, modafinil 100-mg capsule BID) or placebo group (10 subjects). We used the MFI to measure subjective fatigue and used finger tapping and intermittent force generation to evaluate physical fatigability. Subjects also completed the Epworth Sleepiness Scale (ESS) and the Center of Epidemiological Study-Depression Scale. RESULTS:: There were no significant differences at baseline and at 1 month in finger tapping and ESS between the modafinil and placebo groups. At 2 months, the modafinil group had a higher tapping frequency (P <0.05), shorter dwell time (P <0.05), and less fatigability in finger tapping and tended to have lower ESS scores (P <0.12) than the placebo group. However, there was no difference between groups over time for any dimension of the MFI. CONCLUSIONS:: This small study demonstrated that although modafinil may be effective in reducing physical fatigability in PD, it did not improve fatigue symptoms.

AB - BACKGROUND:: Fatigue is a major nonmotor symptom in Parkinson disease (PD). It is associated with reduced activity and lower quality of life. OBJECTIVE:: To determine if modafinil improves subjective fatigue and physical fatigability in PD. METHODS:: Nineteen PD patients who reported significant fatigue in the Multidimensional Fatigue Inventory (MFI) participated in this 8-week study. Subjects took their regular medications and were randomly assigned to the treatment group (9 subjects, modafinil 100-mg capsule BID) or placebo group (10 subjects). We used the MFI to measure subjective fatigue and used finger tapping and intermittent force generation to evaluate physical fatigability. Subjects also completed the Epworth Sleepiness Scale (ESS) and the Center of Epidemiological Study-Depression Scale. RESULTS:: There were no significant differences at baseline and at 1 month in finger tapping and ESS between the modafinil and placebo groups. At 2 months, the modafinil group had a higher tapping frequency (P <0.05), shorter dwell time (P <0.05), and less fatigability in finger tapping and tended to have lower ESS scores (P <0.12) than the placebo group. However, there was no difference between groups over time for any dimension of the MFI. CONCLUSIONS:: This small study demonstrated that although modafinil may be effective in reducing physical fatigability in PD, it did not improve fatigue symptoms.

KW - Fatigue

KW - Parkinson disease/parkinsonism

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=74249114595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249114595&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3181aa916a

DO - 10.1097/WNF.0b013e3181aa916a

M3 - Article

C2 - 19620846

AN - SCOPUS:74249114595

VL - 32

SP - 305

EP - 310

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 6

ER -